Printer Friendly

FDA licenses new hemophilia treatment.

The FDA has licensed a treatment for hemophilia A, a rare, hereditary blood-clotting disorder that affects approximately 15,000 individuals, almost exclusively males, in the United States.

The new treatment, called Xyntha Antihemophilic Factor (Recombinant) Plasma/Albumin Free, is a genetically engineered version of factor VIII, a protein essential for the clotting of blood. Factor VIII, known as an antihemophilic factor, is missing or decreased in patients with hemophilia A.

Xyntha is licensed for the control and prevention of bleeding, which can occur spontaneously or after an accident or injury in patients diagnosed with hemophilia A. Xyntha is also licensed to help prevent surgical bleeding in this patient population.

Xyntha is manufactured using recombinant DNA techniques that enable scientists to create new DNA strands with specific traits, such as the capacity to produce a specific protein.

Xyntha is manufactured by Wyeth Pharmaceuticals Inc., located in Philadelphia.
COPYRIGHT 2008 Advantage Business Media
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Industry News
Publication:Pharmaceutical Processing
Date:Mar 1, 2008
Previous Article:Genmab to buy Minnesota biotech plant from PDL Biopharma.
Next Article:Mix-ups could be worsened by computerized systems.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters